This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MAPS | |
|---|---|
| Name | MAPS |
| Type | Nonprofit research organization |
| Founded | 1986 |
| Founders | Rick Doblin |
| Headquarters | Santa Cruz, California |
| Key people | Rick Doblin |
| Focus | Psychedelic research, psychopharmacology, psychotherapy |
MAPS MAPS is a nonprofit research organization dedicated to scientific research, education, and policy reform related to psychedelic-assisted therapies and related psychopharmacological treatments. The organization sponsors clinical trials, trains therapists, and engages with regulatory agencies, academic institutions, and philanthropic funders to advance therapies for conditions such as post-traumatic stress disorder, anxiety, and depression. MAPS operates at the intersection of clinical research, bioethics, and public policy, collaborating with hospitals, universities, and psychiatric researchers.
The name is an acronym reflecting the organization’s mission and founding vision; its expansion is cited in contemporary literature on psychedelic research, policy advocacy, and harm reduction. Founders and early advocates described the acronym within contexts that included clinical research, therapeutic development, regulatory engagement, and public education. Contemporary treatments, investigator-initiated trials, and philanthropic foundations reference the acronym when discussing programmatic priorities at institutional partners such as Johns Hopkins University, Imperial College London, Harvard Medical School, University of California, San Francisco, and Yale University.
MAPS was established in the mid-1980s amid renewed interest in psychedelic research after a decades-long hiatus following regulatory actions in the 1960s and 1970s. Early milestones included small-scale studies, Establishment of regulatory pathways, and engagement with ethics boards and national regulatory agencies such as the Food and Drug Administration and agencies in the European Union. The group expanded in scope through collaboration with clinical centers including New York University, Massachusetts General Hospital, Mount Sinai Health System, and research teams led by investigators at Johns Hopkins University. Key developments involved phase 2 and phase 3 clinical trials, expanded access programs, and training initiatives for clinicians affiliated with institutions such as UCLA, Columbia University, and Oxford University.
Clinical applications supported by the organization focus on treatment-resistant psychiatric conditions, trauma-related disorders, and palliative care settings. Investigational therapies include assisted psychotherapy using compounds investigated in trials at centers such as Scripps Research, Stanford University School of Medicine, McLean Hospital, and Cedars-Sinai Medical Center. Use cases span inpatient and outpatient protocols, adjunctive psychotherapy frameworks, and harm-reduction programs linked to community health organizations and advocacy groups like Drug Policy Alliance and MAPS Public Benefit Corporation collaborations. Demonstration projects and investigator-initiated protocols have been conducted in partnership with military and veterans’ health systems, academic medical centers, and specialized clinics such as Veterans Health Administration facilities.
Scientific methodologies employed include randomized controlled trials, double-blind placebo-controlled designs, open-label studies, and long-term follow-up cohorts conducted in compliance with institutional review boards at institutions such as National Institutes of Health, Beth Israel Deaconess Medical Center, University College London, and Karolinska Institutet. Protocols specify dosing regimens, psychotherapy modalities, safety monitoring, and adverse-event reporting consistent with guidelines issued by regulatory bodies like the European Medicines Agency and Food and Drug Administration. Pharmacological compounds studied in trials have included synthetic and naturally derived agents investigated alongside psychotherapeutic frameworks developed with input from clinicians linked to NIMH, Johns Hopkins University School of Medicine, and international collaborators such as Imperial College London research groups.
The organization is governed by a board of directors, advisory boards, and scientific review committees comprising clinicians, researchers, and legal experts drawn from universities, hospitals, and policy institutions including Harvard Medical School, Yale School of Medicine, Columbia University Irving Medical Center, and nonprofit funders. Executive leadership coordinates fundraising, grantmaking, and public-facing education while maintaining partnerships with contract research organizations, academic research centers, and clinical training programs at institutions such as University of California, Los Angeles, University of Pennsylvania, and Massachusetts Institute of Technology affiliates. Governance mechanisms include conflict-of-interest policies, data safety monitoring boards, and collaborations with regulatory counsel experienced with filings to agencies including the Food and Drug Administration.
The organization’s activities have prompted debate involving researchers, regulatory authorities, and advocacy groups over issues such as trial design, access pathways, commercialization, and ethical considerations in psychedelic-assisted therapy. Critics from academic, clinical, and policy circles—including commentators at The New England Journal of Medicine forums, watchdog groups, and multidisciplinary ethics panels—have raised questions about evidentiary standards, informed consent models, and the role of private funding from philanthropic entities. Disputes have also occurred regarding training standards for clinicians, interactions with international regulatory frameworks like those of the European Medicines Agency and national health services, and the balance between expedited access and rigorous evidence as discussed in policy debates at venues such as United Nations drug policy meetings.
Rick Doblin Psychedelic research Psilocybin MDMA-assisted psychotherapy Clinical trial Food and Drug Administration European Medicines Agency Johns Hopkins University Imperial College London Harvard Medical School Yale University Stanford University School of Medicine Veterans Health Administration Drug Policy Alliance National Institutes of Health New York University Massachusetts General Hospital Columbia University University of California, San Francisco UCLA Oxford University Scripps Research McLean Hospital Cedars-Sinai Medical Center Mount Sinai Health System University College London Karolinska Institutet NIMH United Nations The New England Journal of Medicine Veterans Health Administration Massachusetts Institute of Technology Beth Israel Deaconess Medical Center Johns Hopkins University School of Medicine University of Pennsylvania Drug Policy Alliance